Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study

BACKGROUND: TNF inhibitors have been used as a treatment for moderate to severe RA patients. However, reliable biomarkers that predict therapeutic response to TNF inhibitors are lacking. In this study, we investigated whether chemokines may represent useful biomarkers to predict the response to TNF...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Arthritis Res Ther
Asıl Yazarlar: Han, Bobby Kwanghoon, Kuzin, Igor, Gaughan, John P., Olsen, Nancy J., Bottaro, Andrea
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2016
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4840903/
https://ncbi.nlm.nih.gov/pubmed/27102921
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-016-0995-0
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller